Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Central Nervous System Neoplasms 2Brain Neoplasms 2Skin Neoplasms 1Sarcoma 1Melanoma 1Glioma 1Carcinoma, Squamous Cell 1Carcinoma, Basal Cell 1Breast Neoplasms 1

Interventions

pembrolizumab 20Cisplatin 17Cetuximab 13Docetaxel 11Paclitaxel 9Carboplatin 9Radiotherapy 8Fluorouracil 6cemiplimab 5130-nm albumin-bound paclitaxel 5Bleomycin 4Radiation 3Pemetrexed 3Panitumumab 3Nivolumab 3Gemcitabine 3Albumin-Bound Paclitaxel 3vandetanib 2talimogene laherparepvec 2selinexor 2motexafin gadolinium 2figitumumab 2brigatinib 2avelumab 2atezolizumab 2alpha-2'-deoxythioguanosine 2advexin 2Taxes 2ON 01910 2Methotrexate 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Carcinoma, Squamous Cell × tozuleristide × Clear all
NCT02097875 2015-04-21

Safety Study of a Fluorescent Marker to Visualize Cancer Cells

Blaze Bioscience Australia Pty Ltd

Phase 1 Completed
21 enrolled
Dermatologic

Carcinoma, Basal Cell, Carcinoma, Squamous Cell, Melanoma, Skin Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡